The biochemical basis of congenital disorders of glycosylation

The enzyme peptide: N-glycanase (EC 3.5.1.52) is an endoglycosidase which cleaves N-linked glycans from incorrectly folded glycoproteins exported from the endoplasmic reticulum during ER-associated degradation (ERAD). Clinical mutations in this enzyme (resulting in loss or decrease in function) are...

Full description

Bibliographic Details
Main Author: Needs, Sarah
Published: Open University 2018
Online Access:https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.765592
id ndltd-bl.uk-oai-ethos.bl.uk-765592
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-7655922019-03-05T15:48:14ZThe biochemical basis of congenital disorders of glycosylationNeeds, Sarah2018The enzyme peptide: N-glycanase (EC 3.5.1.52) is an endoglycosidase which cleaves N-linked glycans from incorrectly folded glycoproteins exported from the endoplasmic reticulum during ER-associated degradation (ERAD). Clinical mutations in this enzyme (resulting in loss or decrease in function) are responsible for the rare congenital disorder termed N-GLY1. N-GLY1 disorder was first identified by next generation sequencing in 2012, and as such there exists little information as to the cellular effects of N-glycanase deficiency. In this study, N-glycanase deficiency was examined in a well-characterised cell model (HEK-293). Cellular effects were examined following pharmacological inhibition of N-glycanase using carbobenzoxy-valyl-ananyl-aspartyl-[O-methyl]-fluoromethylketone (Z-VAD-fmk) and, genetic knockdown by siRNA. Attempts were also made to generate a knockout cell line using CRISPR/Cas9. Using molecular and cellular techniques, this study has confirmed that in HEK-293, pharmacological N-glycanase inhibition or siRNA knockdown does not activate ER stress, oxidative stress or change the glycoprotein profile of the cell. Both treatments were associated with a small increase in ThT fluorescence associated with protein aggregates and identified that autophagy was increased in pharmacological N-glycanase inhibition and siRNA knockdown, and that this likely represents a protective measure. Autophagy dysregulation using ATG13 KO MEF cells found a change in the redox environment of the cell. This effect was further exacerbated in both HEK293, WT MEFs and ATG13 KO MEFs by growth in glucose-free media supplemented with galactose to reduce glycolysis as an energy source. This is suggestive of mitochondrial dysregulation, although no changes in mitochondrial membrane potential or mitochondrial content were identified. Proteomics analysis of immuno-precipitated autophagosomes induced under pharmacological N-glycanase inhibition and siRNA knockdown revealed increased intensity of mitochondrial proteins in these samples indicative of mitophagy which may play a role in the cellular response to impairments of N-glycanase function.Open Universityhttps://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.765592http://oro.open.ac.uk/58286/Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
description The enzyme peptide: N-glycanase (EC 3.5.1.52) is an endoglycosidase which cleaves N-linked glycans from incorrectly folded glycoproteins exported from the endoplasmic reticulum during ER-associated degradation (ERAD). Clinical mutations in this enzyme (resulting in loss or decrease in function) are responsible for the rare congenital disorder termed N-GLY1. N-GLY1 disorder was first identified by next generation sequencing in 2012, and as such there exists little information as to the cellular effects of N-glycanase deficiency. In this study, N-glycanase deficiency was examined in a well-characterised cell model (HEK-293). Cellular effects were examined following pharmacological inhibition of N-glycanase using carbobenzoxy-valyl-ananyl-aspartyl-[O-methyl]-fluoromethylketone (Z-VAD-fmk) and, genetic knockdown by siRNA. Attempts were also made to generate a knockout cell line using CRISPR/Cas9. Using molecular and cellular techniques, this study has confirmed that in HEK-293, pharmacological N-glycanase inhibition or siRNA knockdown does not activate ER stress, oxidative stress or change the glycoprotein profile of the cell. Both treatments were associated with a small increase in ThT fluorescence associated with protein aggregates and identified that autophagy was increased in pharmacological N-glycanase inhibition and siRNA knockdown, and that this likely represents a protective measure. Autophagy dysregulation using ATG13 KO MEF cells found a change in the redox environment of the cell. This effect was further exacerbated in both HEK293, WT MEFs and ATG13 KO MEFs by growth in glucose-free media supplemented with galactose to reduce glycolysis as an energy source. This is suggestive of mitochondrial dysregulation, although no changes in mitochondrial membrane potential or mitochondrial content were identified. Proteomics analysis of immuno-precipitated autophagosomes induced under pharmacological N-glycanase inhibition and siRNA knockdown revealed increased intensity of mitochondrial proteins in these samples indicative of mitophagy which may play a role in the cellular response to impairments of N-glycanase function.
author Needs, Sarah
spellingShingle Needs, Sarah
The biochemical basis of congenital disorders of glycosylation
author_facet Needs, Sarah
author_sort Needs, Sarah
title The biochemical basis of congenital disorders of glycosylation
title_short The biochemical basis of congenital disorders of glycosylation
title_full The biochemical basis of congenital disorders of glycosylation
title_fullStr The biochemical basis of congenital disorders of glycosylation
title_full_unstemmed The biochemical basis of congenital disorders of glycosylation
title_sort biochemical basis of congenital disorders of glycosylation
publisher Open University
publishDate 2018
url https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.765592
work_keys_str_mv AT needssarah thebiochemicalbasisofcongenitaldisordersofglycosylation
AT needssarah biochemicalbasisofcongenitaldisordersofglycosylation
_version_ 1718997385076539392